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ABSTRACT
The base excision repair (BER) pathway is essential
for the removal of DNA bases damaged by alkylation
or oxidation. A key step in BER is the processing of
an apurinic/apyrimidinic (AP) site intermediate by
an AP endonuclease. The major AP endonuclease
in human cells (APE1, also termed HAP1 and Ref-1)
accountsfor.95%ofthetotalAPendonucleaseactiv-
ity, and is essential for the protection of cells against
the toxic effects of several classes of DNA damaging
agents. Moreover, APE1 overexpression has been
linked to radio- and chemo-resistance in human
tumors. Using a newly developed high-throughput
screen, several chemical inhibitors of APE1 have
been isolated. Amongst these, CRT0044876 was
identified as a potent and selective APE1 inhibitor.
CRT0044876 inhibits the AP endonuclease, 30-
phosphodiesterase and 30-phosphatase activities of
APE1 at low micromolar concentrations, and is a
specific inhibitor of the exonuclease III family of
enzymes to which APE1 belongs. At non-cytotoxic
concentrations, CRT0044876 potentiates the cyto-
toxicity of several DNA base-targeting compounds.
This enhancement of cytotoxicity is associated with
an accumulation of unrepaired AP sites. In silico
modeling studies suggest that CRT0044876 binds
to the active site of APE1. These studies provide
both a novel reagent for probing APE1 function in
human cells, and a rational basis for the develop-
ment of APE1-targeting drugs for antitumor therapy.
INTRODUCTION
The DNA base excision repair (BER) pathway is required for
the accurate removal of bases that have been damaged by
alkylation, oxidation or ring-saturation. This pathway also
handles a variety of other lesions including deaminated
bases and DNA single-strand breaks (1). Although there is
more than one sub-pathway of BER (2) in most cases excision
of a damaged base by a DNA glycosylase enzyme leads to the
formation of a potentially cytotoxic apurinic/apyrimidinic
(AP) site intermediate (3,4). This is a target for an AP endonu-
clease, which cleaves the phosphodiester backbone on the 50
side of the AP site via a hydrolytic mechanism (4). The major
AP endonuclease in humancells, APE1 (also calledpreviously
HAP1 and Ref-1), accounts for over 95% of the total AP
endonuclease activity in most cultured human cell lines
(5–8). APE1 is a member of the highly conserved exonuclease
III family of AP endonucleases, named after the Escherichia
coli homologue of APE1 (9). A second family of AP endonu-
cleases is found in most organisms, the prototypical member
of which is E.coli endonuclease IV (10). X-ray crystallo-
graphic analysis on AP endonucleases from bacteria to
human cells, have revealed that members of the exonuclease
III (11,12) and endonuclease IV (13) families are structurally
unrelated, despite being able to catalyze AP site cleavage
reactions that generate identical products.
In common with exonuclease III (14) [and endonuclease
IV (10)] APE1 performs roles in DNA repair other than AP
site processing (15). APE1 exhibits a 30-phosphodiesterase
activity for removal of fragmented sugar moieties which are
found at the 30 end of DNA strand breaks induced by certain
drugs, such as bleomycin, and by ionizing radiation (16).
APE1 also possesses a weak 30-phosphatase activity, a 30–50-
exonuclease activity and an RNaseH activity; however, the
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doi:10.1093/nar/gki781functional signiﬁcance of these additional activities remains
obscure (15). APE1 also plays a role in the recently described
nucleotide incision pathway (17). All of these activities
apparently utilize a single active site in the DNA repair
domain of APE1, which is the region of the protein that
is conserved in exonuclease III. A separate domain in
APE1, located close to the N-terminus, performs a role unre-
lated to the direct repair of DNA damage. This domain of
APE1 performs a redox regulatory function that can maintain
certain transcription factors, such as p53, c-Jun and Hif-1a,
in a reduced and therefore activated state for DNA binding
(18–21).
The action of APE1 on an AP site generates a strand break
with a 30-hydroxyl terminus, which can prime DNA repair
synthesis, and a 50-deoxyribose phosphate (50dRp) terminus.
The 50dRp residue must be removed in order for the repair
process to be completed. This task is accomplished by the dRp
lyase domain present in DNA polymerase b, the enzyme that
also performs the task of ﬁlling in the single base gap thus
formed (22). Repair is then completed by ligation of the nick,
which is generally catalyzed by DNA ligase III in association
with its binding partner XRCC1. This pathway has been
termed ‘short patch’ BER (23).
Several preclinical and clinical studies have been indicated
that APE1 may be an attractive target for anticancer drug
development. Although homozygous deletion of the APE1
homolog in the mouse (APEX) leads to embryonic lethality
(24,25), APEX
± heterozygous mice are hypersensitive to
oxidative stress (26). Depletion of intracellular APE1 also
sensitizes human cells to a variety of cytotoxic agents.
Using either antisense oligonucleotide or RNA interference
approaches, several groups have reported that APE1 down-
regulation confers sensitivity to mono-functional alkylating
agents, such as methylmethane sulfonate (MMS), and oxidiz-
ing agents, such as hydrogen peroxide (27–31). Moreover, a
recent study indicated that severe depletion of APE1 retarded
cell proliferation and led to an accumulation of unrepaired AP
sites (32). APE1 function may also be related to the patho-
genesis of several human cancers, and its expression may have
prognostic and/or predictive signiﬁcance. For example, APE1
is overexpressed in several human tumors (33–40) and its
expression pattern appears to have prognostic signiﬁcance
in cancers of the breast (33), lung (41,42) and bone (31). In
cervical cancers, increased APE1 expression has been shown
to be associated with radioresistance (34), and a high level of
nuclear APE1 was shown to correlate with resistance to
chemotherapy and poor overall survival in patients with
head and neck cancer (39).
Giventhe strongpreclinicalandclinicalevidencethatAPE1
may be a promising anticancer-drug target, a drug discovery
programme was undertaken. As APE1
 /  human cell lines
cannot be generated, an important additional aim of this
study was to generate laboratory reagents to probe the func-
tional consequences of APE1 inactivation. A ﬂuorescence-
based, high-throughput assay was developed to screen for
inhibitors of the AP endonuclease activity of APE1. A small
molecule chemical library was screened and several inhibitors
of APE1 were isolated. Amongst these, CRT0044876 was
identiﬁed as a speciﬁc APE1 inhibitor, and this agent has
been analyzed here in detail. At non-toxic concentrations,
CRT0044876 potentiated the cytotoxicity of several DNA
damaging agents, which generate damage that is repaired in
the BER pathway, including some currently-used anticancer
drugs. This potentiation of cytotoxicity was shown to correlate
with an accumulation of unrepaired AP sites in CRT0044876-
treated cells.
MATERIALS AND METHODS
Enzymes, chemicals and oligonucleotides
Human APE1 and uracil-DNA glycosylase were puriﬁed to
homogeneity as described previously (43,44). E.coli endonu-
clease III and endonuclease IV were obtained from Trevigen.
E.coli exonuclease III and BamHI restriction endonuclease
were obtained from New England Biolabs. Topoisomerase I
was obtained from Promega. Whole cell extracts were pre-
pared by a method as described previously (45). Protein con-
centration was determined using the BioRad Coomassie blue
assay with bovine serum albumin (BSA) as a standard.
MMS, 5-hydroxymethyl-20-deoxyuridine (hmdUrd), camp-
tothecin and mechlorethamine hydrochloride (nitrogen mus-
tard) were all purchased from Sigma-Aldrich. Temozolomide
was a gift from Prof. Malcolm Stevens, University of Notting-
ham, UK. Stock solutions of potential APE1 inhibitors and
camptothecin were dissolved in DMSO. MMS, hmdUrd,
temozolomide and mechlorethamine hydrochloride were dis-
solved in phosphate buffered saline (PBS).
The oligonucleotides; 50-F-GCCCCCXGGGGACGTAC-
GATATCCCGCTCC-30 and 30-Q-CGGGGGCCCCCTGCA-
TGCTATAGGGCGAGG-50 (where F is Fluorescein, Q is
Dabcyl and X is Terahydrofuran, an abasic site analog)
were custom-made by Eurogentec Ltd. A uracil-containing
18mer oligonucleotide 50-CTCGCAAGUGGGTACCGA-30
and its complementary oligonucleotide, 50-TCGGTACCCG-
CTTGCGAG-30 were synthesized by the Cancer Research UK
central services laboratory (Clare Hall, UK). The 30-phospho-
glycolate (PG) substrate (50-CAATAGAGTAACACGGpg-30)
was synthesized by Eurogentec using the method of Urata and
Akagi (46), in which the 30-phosphoglyceryl residue is oxi-
dized sequentially by sodium periodate (NaIO4) and sodium
chlorite (NaClO2). This oligonucleotide, which has been char-
acterized previously (16), was puriﬁed by high-performance
liquid chromatography (HPLC) and the presence of 30-PG was
conﬁrmed by mass spectrometry.
Fluorescence-based, high-throughput screening
A library of 5000 ‘drug-like’ compounds was purchased from
Maybridge Chemicals (Tintagel, UK). A high-throughput
assay to identify potential APE1 inhibitors was developed
(Figure 1). Brieﬂy, APE1 enzyme (0.7 nM) was incubated
with or without library compounds in a buffer system com-
prising of 50 mM Tris–HCl (pH 8.0), 1 mM MgCl2,5 0m M
NaCl and 2 mM dithiothreitol (DTT) at 37 C for 10 min. The
sequence 50-F-GCCCCCXGGGGACGTACGATATCCCGC-
TCC-30 and its complementary oligonucleotide 30-Q-CGGG-
GGCCCCCTGCATGCTATAGGGCGAGG-50 were annealed
and the reaction was initiated by addition of the annealed
substrate. Fluorescence readings were taken continuously dur-
ing a 25 min incubation at 37 C (using a Molecular Devices
Spectramax Gemini plate reader and Softmax Pro software
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Figure 1. ScreeningforAPE1inhibitors.(a)Fluorescence-basedassayforAPE1activity.ADNA30merduplexwasdualtaggedwithaquench(DABCYL)—fluor
(FAM)pair.Separationofthequenchandfluoroccursfollowingcleavageofthesingleabasicsite(tetrahydrofuran).(b)Fluorescencesignalmeasurementsusingthe
APE1 assay. Increasing amounts of APE1 were mixed with 100 nM oligonucleotide substrate under conditions described in the Materials and Methods. A
concentration dependent rise in fluorescence indicated AP site cleavage activity by APE1. (c) Scheme for the gel-based AP site cleavage assay. (d) Example
oftheassay,usingabacterialcellextractexpressingrecombinantAPE1.The18meruncutsubstrate(lane1)and8merAPE1cleavageproduct(lane3)areindicated.
Immunodepletion of APE1 in the extract using protein A-sepharose beads abolished the cleavage activity of the extract (lane 2) confirming that cleavage was
mediated by APE1.
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530 nM Emission). If the DNA is cleaved at the abasic site
at position 7 from the 50 end by APE1, the 6mer Fluorescein-
containing molecule can dissociate from its complement
by thermal melting. As a result, the quenching effect of the
30-Dabcyl molecule (which absorbs ﬂuorescein ﬂuorescence
when in close proximity) is lost, and APE1 activity can be
measured indirectly as an increase in ﬂuorescence signal.
Before the use of this assay for screening, it was shown
that the 6mer Fluorescein-containing oligonucleotide did
indeed fully dissociate from the complementary oligonu-
cleotide when incubated at 37 C (data not shown).
AP site cleavage assay
A uracil-containing oligonucleotide [50-CTCGCAAGUGGG-
TACCGA-30] was 50 end-labeled with [g-
32P]ATP in a 20 ml
reaction containing 50 mM Tris–HCl (pH 8.0), 10 mM MgCl2,
0.1 mM EDTA, 5 mM DTT, 20 mCi [g-
32P]ATP and 1 U T4-
polynucleotide kinase. The mixture was incubated at 37 C for
1 h, and the reaction was terminated by the addition of 50 ml
TE buffer. The DNA was then passed through a Sephadex G-
25 spin column (Roche). The radiolabeled, uracil-containing
oligonucleotide was then annealed to an equimolar amount
of complementary oligonucleotide in TE buffer containing
100 mM KCl by incubation at 90 C for 3–5 min, followed
by a slow cooling to room temperature. The annealed DNA
substrate (50 pmol) was pretreated with uracil-DNA glycosy-
lase (6.25 pmol) in 10 mM HEPES (pH 7.9), 1 mM EDTA and
100 mM KCl. The reaction mixture was incubated at 37 C for
1 h. The resulting AP site indicated was chemically reduced by
the addition of sodium borohydride to 0.1 M. After incubation
on ice-cold for 10 min, the reaction buffer was exchanged to
TE buffer by a passage through a Sephadex G-25 spin column.
BER reaction buffer comprised 40 mM HEPES–KOH
(pH 7.8), 5 mM MgCl2, 0.5 mM DTT and 0.1 mM EDTA.
A1 0ml AP site cleavage reaction comprised of BER buffer
mix, puriﬁed protein (3.3 nM ﬁnal concentration of APE1) and
0.75 ng reduced AP site double-stranded oligonucleotide. The
mixture was incubated at 37 C for 1 h. A total of 1 ml of stop
buffer (50% glycerol, 10 mM Tris–HCl, 1 mM EDTA, 0.1%
bromophenol blue and 0.1% Xylene cyanol) was added, and
the sample mixture was denatured at 90–100 C for 2 min. The
sample was then run on a 15% TBE Criterion  Pre-Cast Gel
(Bio-Rad), with electrophoresis at a constant current of 30 mA
for 30 min, and the radiolabeled substrate and reaction prod-
ucts were visualized using a phosphorImager (Molecular
Dynamics). The inhibitory activity of potential APE1-
targeting compounds were analyzed at drug concentrations
ranging from 0.1 to 100 mM. The resolved radiolabeled
bands were quantiﬁed using ImageQuant software analysis,
and IC50 values were calculated by determining the concen-
tration of the inhibitor that reduced APE1 activity to 50% of
the control values.
Similar AP site cleavage assays were set up to measure
exonuclease III activity [in a 10 ml reaction vol containing
10 mM Bis-Tris-Propane–HCl (pH 7.0), 10 mM MgCl2,1m M
DTT, reduced AP site-containing double-stranded oligonu-
cleotide (0.75 ng) and 0.1 U of Exonuclease III (New England
BioLabs) and incubated for 1 h at 37 C]. Endonuclease IV was
assayed in a similar manner [in a 10 ml reaction volume
containing 10 mM HEPES–KOH, 100 mM KCl (pH 7.4),
reduced AP site-containing double-stranded oligonucleotide
(0.75 ng) and 0.01 U of Endonuclease IV (TREVIGEN )].
Reactions were incubated for 1 h at 37 C. In assays containing
HeLa whole cell extracts, a 10 ml reaction comprising of
10 mM HEPES–KOH (pH 7.4), 100 mM KCl, the reduced
AP site-containing double-stranded oligonucleotide (0.75 ng)
and 30 ng of HeLa whole cell extract was used, and the reac-
tion mix was incubated for 1 h at 37 C.
30-phosphodiesterase activity of APE1
The 30-PG containing oligonucleotide (50-CAATAGAGTAA-
CACGGpg-30) was 50 end labeled with [g-
32P]ATP using T4-
polynucleotide kinase and unincorporated label removed on a
Sephadex G-25 spin column. To prepare the 30-PG duplex
substrate, the labeled 30-PG oligonucleotide was mixed with
an equimolar amount of the oligonucleotide 50-pCGAC-
CAGTCCCTGCCAATC-30, and both were annealed with a
2-fold excess of the oligonucleotide 50-GATTGGCAGGGAC-
TGGTCGGCCGTGTTACTCTATTG-30 at 90 C for 3–5 min
followed by slow a cooling to room temperature to create an
oligonucleotide with a 1 nt gap ﬂanked by 30-PG and 50-phos-
phate ends. APE1 (0–300 fmol) was incubated with 300 fmol
duplex oligonucleotide per reaction in 20 ml reaction buffer
containing 50 mM HEPES–KOH (pH 7.8), 50 mM KCl,
10 mM MgCl2, 0.5 mM EDTA, 1.5 mM DTT, 8.5% glycerol,
2 mM ATP and 50 mg/ml BSA. For inhibitor studies, APE1
(150 fmol) was preincubated with inhibitor (0–10 mM) for
10 min on ice-cold before addition of the substrate. Reactions
were incubated for 10 min at 30 C and 20 ml formamide
loading dye was added (95% formamide, 0.02% Xylene cya-
nol and 0.02% bromophenol blue) and the samples were
heated to 95 C for 3 min. Products were analyzed by 20%
denaturing PAGE, and the gels were exposed to storage phos-
phor screens at 4 C before analysis by phosphorimaging.
30-phosphatase activity of APE1
Through its AP-lyase activity, E.coli formamidopyrimidine
[fapy]- DNA glycosylase (fpg) cleaves both 30 and 50 to the
AP site thereby removing the AP site and leaving a one
base gap between 50 and 30-phosphate residues. The 30-phos-
phatase activity of APE1 removes the 30-phosphate group and
restores a 30-OH priming terminus. The abasic oligonu-
cleotide substrate was prepared as described above. One
unit of fpg was added to this reaction and the mixture
was incubated at 37 C for 30 min. To the above reaction
mix, 3.3 nM of APE1 was added and the sample was incu-
bated at 37 C for 1 h. A total of 1 ml of stop buffer (50%
glycerol, 10 mM Tris–HCl, 1 mM EDTA, 0.1% bromophenol
blue and 0.1% Xylene cyanol) was added at the end of the
reaction and the sample mix was denatured at 90–100 C for
2 min. The sample was then electrophoresed in a 20% TBE-
urea gel at a constant current of 30 mA for 2 h and imaged
using a phosphorImager analysis (Molecular Dynamics). To
test the inhibitory activity of the compounds on the 30-phos-
phatase activity of APE1, a serial dilution of the potential
inhibitor of APE1 was set up in the above reaction mix (after
the AP lyase reaction of fpg) and the assay was perfomed as
described previously.
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BamHI activity was assayed using conventional restriction
digestion of an 8.8 Kb plasmid (b-gal-pcDNA; Invitrogen)
containing two BamHI recognition sites. Reaction products
were analyzed on a 0.8% agarose gel (with ethidium bromide
at 0.03 ng/ml).
Topoisomerase I relaxation assay
fX174 RF I DNA (New England Biolabs) was used for mea-
suring topoisomerase I DNA relaxation activity. Brieﬂy,
200 ng of the DNA was added to a reaction mixture containing
50mMTris–HCl(pH7.9),5mMMgCl2,50mMNaCl,1mg/ml
BSA, 1 mM DTT and 0.25 U of wheat germ topoisomerase I
andthemixturewasincubatedfor1hat37 C.Atotalof1mlof
stop buffer (50% glycerol, 10 mM Tris–HCl, 1 mM EDTA,
0.1% bromophenol blue and 0.1% Xylene cyanol) was added
attheendofthereactionandthesampleswere electrophoresed
on a 1% agarose gel. The DNA was stained with 0.03 mg/ml of
ethidium bromide.
Clonogenic survival assays
HT1080 ﬁbrosarcoma cells were grown in 2% RPMI medium
[supplemented with penicillin 0.06 g/l, streptomycin 0.1 g/l
(pH 7.0), 10% fetal bovine serum (FBS, Life Technologies)
and 4 mM glutamine]. Only cells with a plating efﬁciency of
>60% were used for clonogenic survival analysis. Tissue cul-
ture dishes (10 cm) were seeded with 500 cells per dish and the
culture was maintained in a humidiﬁed incubator at 37 Ci na n
atmosphere of 5% CO2 and 95% air. To evaluate the toxicity
proﬁle of putative APE1 inhibitors, various concentrations
(100–500 mM) of inhibitor were added to the medium, and
cultures were incubated for 7–10 days until cell colonies were
formed. Colonies were ﬁxed [75% (v/v) methanol, 25% (v/v)
acetic acid] for 30 min and stained with crystal violet (1 mg/ml
indistilledwater)for4hatroom temperature. Visible colonies
were counted on a colony counter (Stuart Scientiﬁc, UK).
To evaluate the potentiation of cytotoxicity of DNA dam-
aging agents by putative APE1 inhibitors, 500 cells were pla-
ted in the absence or presence of APE1 inhibitor and allowed
to adhere to the plate for 1 h. Cells were then exposed to one of
the following DNA damaging agents in the concentration
range indicated in parentheses: MMS for 1 h (100–500 mM),
temozolomide for 1 h (200–1400 mM), mechlorethamine
hydrochloride for 1 h (1–3 mM), hmdUrd for 24 h (1–4 mM),
camptothecin for 24 h (2.5–50 nM), or UV light [4 Jm
 2–
20 Jm
 2, using a UV Stratalinker (254 nM UV light). The
mediumwas removed and1mlofPBS wasadded toeach plate
prior to exposure to UV light]. Analysis of colony formation
and counting was done as described above. All experiments
were performed in triplicate and the ﬁnal concentration of
DMSO was <1% when cells were treated with compounds
dissolved in this solvent.
Quantification of AP sites in genomic DNA
AP sites were quantiﬁed as described by Nakamura et al. (47).
Genomic DNA was extracted from a pellet of 5 · 10
6 cells
using the guanidine/detergent lysis method. Brieﬂy, 0.5 ml of
DNAzol  (Helena Biosciences) was added to the pellet and
the cell lysate was gently passed several times through a
pipette. The resultant viscous solution was centrifuged at
10000 g for 10 min at 25 C. DNA was precipitated from
the supernatant using 0.25 ml of 100% ethanol by gently
inverting the tube 5–8 times at room temperature for 1–3 min.
The DNA was later removed by spooling with a pipette and
washed twice in 0.4 ml of 75% ethanol. The DNA was then
solubilized in TE buffer (pH 8.0), and the ﬁnal concentration
was adjusted to 100 mg/ml [using a spectrophotometer
(Nanodrop  ND-1000)]. AP site determinations were per-
formed on the genomic DNA using an aldehyde reactive
probe assay kit using the protocol provided by the manufac-
turer (Dojindo Molecular technologies, Inc.). All experiments
were performed in triplicate.
Molecular modeling
CRT0044876 was docked into two separate structures of
APE1, crystallized in the presence and absence of DNA,
using Autodock3.0.5 (48). Coordinates for the DNA bound
protein were obtained from 1DE9.pdb (49). All crystallo-
graphic water molecules, DNA, protein chain B and one of
the metals were removed. The Mn atom bound to chain A was
retained but renamed as Zn. Missing sidechain heavy atoms
were added manually using Sybyl6.9 (http://www.tripos.com).
Coordinates for the unligated protein were taken from
1BIX.pdb (11). Again, water molecules and all metal ions
except the one bound in the active site, which was renamed
to Zn, were removed. Polar hydrogens, Kollman united atom
charges, fragmental volumes and solvation parameters were
added to both structures using Autodock Tools (http://www.
scripps.edu/mb/olson/doc/autodock/tools.html).
All atom model of the APE1 inhibitor was built and
assigned as Gasteiger-Marsili charges in Sybyl6.9. The mole-
cule was modeled containing a carboxylate group and there-
fore, had an overall charge of  1. Using the Autotors utility
within Autodock3, the coordinates and charges of all non-
polar hydrogen atoms were merged, and the ring carbon
atoms were identiﬁed as aromatic. Additionally, the bonds
between the indole C2 and the carboxylate carbon, and
between C7 and the nitro group were deﬁned as rotatable.
Autorgid3 (48) was used to calculate the grid maps before
docking of the inhibitor. A grid consisting of 126 points in
each (x, y, z) dimension, with a grid spacing of 0.375 A ˚ and
centred on the backbone carbonyl atom of Glu96 was used.
The Lamarckian genetic algorithm within Autodock3 (48) was
used for the docking runs. All parameters were set to the
default values, except for the number of runs, which was
increased from 10 to 100. The 100 resultant docked confor-
mations were clustered using an in-house program written by
V. Lesk (Structural Bioinformatics Group, Imperial College,
London, UK). A greedy algorithm was employed using the
structure with the best predicted binding energy as the initial
seed. A cut-off of 1.0 s was selected, and all atoms were
included in the calculation. The program was able to take an
account of the symmetry in the nitro and carboxylate groups.
RESULTS
A high-throughput assay for the identification of
APE1 inhibitors
Ahigh-throughput,ﬂuorescence-based,APsitecleavageassay
was developed for use in a 96-well plate format (Figure 1a).
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contain a ﬂuor-quench pair containing a ﬂuorescein moiety on
the 50 end of one DNA strand adjacent to a Dabcyl quenching
group on the 30 end of the complementary strand. In this state,
the ﬂuorescence of the ﬂuorescein moiety is quenched. The
principle of the assay is that cleavage by APE1 of the phos-
phodiester backbone 50 to the single tetrahydrofuran (a stable
AP site analog) residue at position 7 of the ﬂuorescein-
containing oligonucleotide yields a 6mer product that cannot
remain base-paired to its complement at 37 C (Figure 1a).
This thermal denaturation separates the ﬂuor-quench pair, pro-
ducing a ﬂuorescent signal that can be detected using a plate
reader. Inhibitors of APE1 would be expected to block the AP
endonuclease reaction (Figure 1b), and hence eliminate the
ﬂuorescent signal.
A chemical library of 5000 compounds, which represents a
structurally-diverse set acquired from commercial sources and
considered to be ‘drug-like’ in structure, was screened using
this assay system. The compounds were initially screened at a
ﬁxed concentration of 5 mM. The primary hits (showing >50%
inhibition of APE1) from this screen were re-tested in dupli-
cate, and those that consistently inhibited APE1 activity by
>50% were taken for further analysis. As a ﬁrst test of target
selectivity, and to eliminate compounds that non-speciﬁcally
interfered with the ﬂuorescence detection system, selected
compounds were screened for their inability to inhibit
HpaII restriction endonuclease in a similar ﬂuor-quench
oligonucleotide assay format. After an initial round of hit
analogue reordering, 56 compounds were identiﬁed as poten-
tial APE1 inhibitors, all of which had an IC50 of <10 mM.
The56compounds fromthe primaryscreen were then tested
in a more direct AP site cleavage assay in which the product of
cleavage could be visualized directly. In this assay (presented
schematically in Figure 1c), APE1-mediated cleavage of the
AP site generates an 8mer
32P-end-labeled product that can be
separated from uncleaved substrate on a polyacrylamide gel
(Figure 1d). When screened at 100 mM, 15 of the selected
compounds completely inhibited APE1-mediated AP site
cleavage. Each of these compounds was then re-tested for
inhibitory activity in this gel-based assay over a wide concen-
tration range. From this analysis, CRT0044876 was taken for
further study. CRT0044876 had an IC50 for inhibition of APE1
of 3 mM and not only inhibited AP site cleavage catalyzed by
puriﬁed APE1, but also cleavage directed by APE1 in a HeLa
whole cell extract (Figure 2).
Specificity testing on CRT0044876
It was possible that CRT0044876 was acting as a non-speciﬁc
inhibitor of APE1. For example, if this compound were to bind
directly to the AP site, in a manner analogous to that of meth-
oxyamine (50), it would be expected to inhibit the action of
any AP endonuclease enzyme. To address this possibility, a
series of speciﬁcity analyses were undertaken. Amongst these,
was atestofthe abilityofCRT0044876toinhibitenzymesthat
interact with DNA and catalyze phosphodiester bond cleavage
by mechanisms similar to or different from that used by
APE1. However, no evidence for inhibition of BamHI restric-
tion endonuclease or topoisomerase I was obtained even at
CRT0044876 concentrations of 100 mM (Supplementary
Figure 1).
As an additional and more directed analysis of speciﬁcity,
the inhibitory effect of CRT0044876 on exonuclease III and
endonuclease IV was analyzed. These two bacterial AP
endonucleases operate via a similar hydrolytic mechanism,
but show no structural similarity to one another (11–13).
Exonuclease III was chosen because it is the bacterial homo-
logue of APE1, and, as such, has a very similar active site
structure (11,12). As shown in Figure 3, CRT0044876 inhib-
ited both the exonuclease and AP endonuclease activities of
exonuclease III, but showed no inhibitory activity towards
endonuclease IV. Taken together, these data argue against
CRT0044876 acting via a mechanism involving direct AP
site binding, in a manner analogous to methoxyamine, and
suggest the possibility that CRT0044876 targets the active
site of exonuclease III/APE1 family members.
If the single DNA repair active site of APE1 were the target
for CRT0044876, it might be expected that all of the enzym-
atic activities exhibited by APE1 would be inhibited by
CRT0044876.Moreover,itmightbeexpectedthattherewould
be a similar IC50 for inhibition of these activities to that for
inhibition of the AP endonuclease activity of APE1. The data
presented in Figure 4 indicate that, indeed, this is the case.
CRT0044876 inhibited the 30-phosphoglycolate diesterase
activity of APE1 with an IC50 of  5 mM (Figure 4a and b).
A similarly potent inhibition of 30-phosphatase activity was
also observed (data not shown). These data provide additional
evidence that the inhibitory action of CRT0044876 on APE1 is
independent of direct AP site binding.
Effects of CRT0044876 on human cell lines
The data presented suggest that CRT0044876 can potently
and selectively inhibit APE1 in vitro. However, in order to
have general utility as a BER inhibitor, it was important to
conﬁrm that CRT0044876 could block APE1 function in
living cells. Recent siRNA studies indicated that, in the
absence of functional APE1, there is an accumulation of unre-
paired AP sites in cells treated by alkylating agents (32). Using
the same aldehyde reactiveprobe assayasutilizedin that study
(32), and described previously by Nakamura et al. (47), a
statistically signiﬁcant increase in AP site accumulation was
found inHT1080ﬁbrosarcoma cellstreatedwith CRT0044876
alone (Figure 5). As expected, MMS treatment of HT1080
cells also caused an elevation in the level of AP sites. How-
ever, the combination of MMS and CRT0044876 led to a
synergistic increase in the level of AP sites, consistent with
the notion that CRT0044876 was able to inhibit APE1 activity
in vivo (Figure 5).
To investigate whether this apparent inhibition of APE1 by
CRT0044876 had biological consequences, survival analyses
were undertaken in HT1080 cells. Initially, CRT0044876 was
tested for its inherent toxicity, but was shown to be non-toxic
to HT1080 cells at any dose relevant to the analyses described
in this study (>95% survival at concentrations up to 400 mM;
data not shown). Next, the effect of combining CRT0044876
with DNA damaging agents was tested. The most commonly
studied laboratory agent for analysis of AP endonuclease deﬁ-
ciency is the monofunctional alkylating agent, MMS. Hence
this agent was tested initially. As shown in Figure 6a, whereas
500 mM MMS alone produced <10% cell killing, it was
possible to kill 99% of HT1080 cells by exposure to the
4716 Nucleic Acids Research, 2005, Vol. 33, No. 15combination of MMS and a non-toxic concentration of
CRT0044876 (200 mM). Similar results were seen in HeLa
cervical carcinoma cells and in MDA-MB-231 breast carcin-
oma cells (data not shown). Because MMS is not used clini-
cally, it was important to conﬁrm this potentiation of
cytotoxicity using a widely-used chemotherapeutic alkylating
agent. The data in Figure 6b indicate that a similarly dramatic
potentiation of temozolomide toxicity was observed in
HT1080 cells treated with CRT0044876. Potentiation of cyto-
toxicity was also seen with hydrogen peroxide that causes
oxidative DNA base damage (data not shown).
It was possible that these effects of CRT0044876 reﬂected
a non-speciﬁc response to any form of DNA damage, and not
a speciﬁc inhibition of the BER pathway. To address this,
additional survival analyses were conducted using agents
that generate DNA damage that is not repaired by BER.
(a)
(b)
(c)
Figure2.IdentificationofCRT0044876asanAPE1inhibitor.(a)InhibitoryprofileofCRT0044876.DNAsubstrate(lane1);substratewithAPE1(lane2);substrate
withAPE1anddifferentconcentrationsofCRT0044876(lanes3–10).Lane11showsthattheDMSOsolventdidnotinhibitAPE1.(b)Quantificationofthedatafrom
panelAshowingthepercentageinhibitionofAPE1asafunctionofCRT0044876concentration.TheIC50valueforAPE1inhibitionbyCRT0044876wascalculated
to be 3.06 mM. (c) CRT0044876 inhibited the AP site cleavage activity in HeLa whole cell extracts (WCE).
Nucleic Acids Research, 2005, Vol. 33, No. 15 4717Consistent with CRT0044876 being a speciﬁc BER inhibitor,
CRT0044876 did not potentiate the cytotoxicity of UV light
(Figure 6c), nitrogen mustard (Figure 6d), or camptothecin
(Figure 6e). To provide further evidence to substantiate this
point, cytotoxicity studies were also conducted with hmdUrd.
This compound is incorporated into DNA, and can be excised
by the SMUG1 glycosylase to generate an AP site. Neverthe-
less, hmdUrd is generally regarded as innocuous unless faulty
repair is invoked. For example, previous studies have shown
that hmdUrd is highly toxic in mouse cells lacking functional
DNA polymerase b, but not in wild-type cells, because of
the build up of toxic BER intermediates that are not pro-
cessed adequately due to the polymerase b deﬁciency (51).
Consistent with CRT0044876 being a speciﬁc BER inhibitor,
a strong potentiation of hmdUrd cytotoxicity was seen in
CRT0044876-treated cells (Figure 6f).
Zeocin  is a formulation of Phleomycin D1, a copper–
chelated glycopeptide that belongs to the bleomycin family
(a)
(b)
(c)
Figure3.CRT0044876isaninhibitoroftheexonucleaseIIIfamilyofAPendonucleases.(a)CRT0044876inhibitsthe30–50-exonucleaseactivityofexonucleaseIII.
DNAsubstrate(lane1asindicatedontheright);exonucleaseIIIalone,whichgenerateddigestionproductsfromthesubstrate,asindicatedontheright(lane2);effects
of increasing concentrations of CRT0044876 on the exonuclease activity (lanes 3–7). (b) CRT0044876 inhibits the AP endonuclease activity of exonuclease III.
Lanes as per (a). (c) CRT0044876 does not inhibit the AP endonuclease activity of endonuclease IV. Lanes as per (a).
4718 Nucleic Acids Research, 2005, Vol. 33, No. 15of anti-tumor antibiotics. One lesion characteristic of the bleo-
mycins is a strand break with a 30-PG terminus. Apart from
processing AP sites, APE1 has been shown to be critically
involved in the removal of 30-PG termini (16). A strong poten-
tiation of Zeocin cytotoxicity was seen in CRT0044876-
treated cells (Figure 6g). This is entirely consistent with the
biochemical data presented above showing that CRT0044876
inhibited the 30-PG diesteraseactivityofAPE1. Ionizing radia-
tion induces single-strand DNA breaks, double-strand DNA
breaks, oxidative DNA base damage and many other toxic
lesions. BER, non-homologous end rejoining (NHEJ) and
homologous recombination (HR) are some of the DNA repair
processes involved in the repair of such damage (1).
CRT0044876 did not potentiate the cytoxicity of ionizing
radiation (Figure 6h). This may be because BER is only
one of the many pathways that are involved in the repair of
ionizing radiation-induced lesions.
In silico modeling of CRT0044876 binding to APE1
The ﬁnding that CRT0044876 can inhibit two exonuclease III
family members, but not endonuclease IV or a number of other
DNA cleaving enzymes, strongly suggested that this com-
pound targets the APE1 active site. To investigate how this
might occur, an in silico modeling approach was undertaken
(Figure 7). CRT0044876 was docked to two X-ray crystal
structures of APE1 using Autodock3 (Materials and Methods).
In the ﬁrst structure, 1DE9.pdb, the protein was crystallized
bound to DNA that had been cleaved at the phosphodiester
bond50 totheabasic site.Astheresolutionofthiscomplexwas
relatively poor, a second structure, 1BIX.pdb, with only metal
ions bound was also selected from the PDB. After removal of
all HETAM groups, except the catalytic metal, the two pro-
teins were prepared for the Autodock calculations as described
in the Materials and Methods. CRT0044876 was modeledwith
the carboxylic group in the ionized form, as would be expected
at neutral pH. Both the bonds from the indole ring to the
carboxylate group, and the nitro group of CRT0044876,
were free to rotate in the calculations.
Using Autodock3, 100 complexes of CRT0044876 docked
to APE1 from both 1DE9.pdb and 1BIX.pdb were generated
and the conformations were clustered using an in-house pro-
gram(writtenbyV.Lesk)anda1.0scutoff.Thesolutionwith
the best predicted binding energy from each cluster was
selected as a representative conformation for the cluster.
The clusters were ranked by the binding energy of the repre-
sentative molecules and by their population size.
For both protein structures, the two major drug binding
modes identiﬁed were in the active site. Binding mode 1
(Figure 7b) resulted in the indole ring of CRT0044876
Figure 4. CRT0044876inhibitsthe30-phosphodiesteraseactivityofAPE1.(a)Assaydesign.Thesubstratecontainsanend-labeled16meroligonucleotidewitha30-
PGmoiety.APE1removesthe30-PGresiduetoproducea30-OHresidue,whichhasafastermobilityona20%polyacrylamidegel(panelb).Lanes1–5showanAPE1
concentration-dependent increase in conversion of the 30-PG to 30-OH. Lanes 6–10 show that CRT00044876 inhibited the 30-phosphodiesterase activity of APE1
(protein fixed at 150 fmol).
Figure 5. Accumulation of AP sites in CRT0044876 treated human HT1080
cells.QuantificationofthenumberofAPsitesper100000bpofnuclearDNAin
untreatedcellsandincellstreatedwithCRT0044876alone,MMSalone,orthe
combinationofCRT0044876andMMS(asindicatedinthekeybelowthebars).
Samplesweretakenbetween1and2hafterdrugexposureasindicated.Values
represented the mean of three independent determinations. Error bars denote
Standard Errors of the mean.
Nucleic Acids Research, 2005, Vol. 33, No. 15 4719being located in the abasic deoxyribose binding pocket, bor-
dered by residues Phe-266, Trp-280 and Leu-282. The nitro
group was orientated away from the bulk of the protein
towards the sidechain of Arg-177 and the carboxylate group
was coordinated to the metal ion. This binding mode was the
major one (top ranked energy and 25 out of 100 runs) when the
X-raystructure1DE9.pdbwasused.Thesecondrankedcluster
by both energy and population deﬁned binding mode 2. Again,
the carboxylate group coordinated with the metal ion, but the
nitro group was seen to hydrogen bond to the sidechain of
(a)
(b)
(c)
(d)
4720 Nucleic Acids Research, 2005, Vol. 33, No. 15Arg-156. A hydrogen bond could also be formed from the
indole NH to the hydroxyl oxygen of Tyr-171 (Figure 7b).
Both binding modes 1 and 2 were also located when 1BIX.pdb
was used for protein coordinates.
DISCUSSION
We have developed a robust and facile high-throughput
screening assay for the identiﬁcation of inhibitors of the
(e)
(f)
(g)
(h)
Figure 6. Clonogenic survival analysis. The percentage survival of HT1080 cells as a function of drug dose or radiation dose is indicated in (a–h). In each case the
filled circles indicate the survival for cells exposed to the DNA damaging agent alone, and the open circles indicate the survival for cells exposed to the damaging
agent in the presence of 200 mM CRT0044876.
Nucleic Acids Research, 2005, Vol. 33, No. 15 4721APE1 protein. This screening methodology is suitable for
analysis of inhibitors of any AP site-processing enzyme that
cleaves the phosphodiester backbone. Even enzymes that do
not directly break the DNA backbone such as some DNA
glycosylases, can be analyzed using the assay, because the
AP site generated by their action can easily be chemically
or enzymatically cleaved in a modiﬁed 2-stage assay proce-
dure. Indeed, we would propose that this assay system has far
wider utility as a drug screening methodology in which it can
readily be adapted for use in the analysis of other DNA modi-
fying enzymes that cleave or unwind the duplex. Amongst
several putative APE1 inhibitors identiﬁed using this assay,
we chose to focus on CRT0044876 because of its potency,
selectivity and lack of inherent toxicity to human cell lines.
Other than exonuclease III, the APE1 homologue in bacteria,
we have yet to identify any DNA modifying enzyme that is
inhibited by CRT0044876 at concentrations of up to 100 mM.
Currently available inhibitors of AP endonuclease function,
such as methoxyamine (which is in phase I clinical trials for
solid tumors) directly target the AP site in the DNA (50), not
the APE1 enzyme. We would argue that targeting DNA repair
enzymes in human cells is a more promising strategy for the
inhibition of DNA repair during cancer chemotherapy because
APE1 performs DNA repair roles in addition to removal of AP
sites. In particular, it is likely that the 30-phosphodiesterase
activity of APE1 is important in the protection of cells against
the toxic effects of certain agents, such as bleomycin, that
generate DNA strand breaks associated with a fragmented
sugar group at 30 terminus. These fragments prevent the prim-
ing of DNA repair synthesis and must be removed. Indeed,
APE1 has been shownto be the major 30-PG diesterase activity
in human cells (16).
This study provides a clear preclinical proof-of-principle
that targeting the DNA base excision repair pathway can
potentiate the cytotoxic effects of certain DNA damaging
agents, including clinically-used alkylating agents. Clearly,
these ﬁndings have signiﬁcant translational implications.
While we would propose that the current ﬁndings provide
important validation of APE1 as an anticancer drug target,
it is likely that further development will be required before
a genuine clinical lead compound can emerge. One approach
to the development of the next generation of APE1 inhibitors
will be to utilize structure-aided design. The modeling data
reported here provides the objective evidence that
CRT0044876 targets the APE1 active site, which is entirely
consistent with speciﬁc targeting of exonuclease III family
members by this compound. Future analyses will include
co-crystallization of APE1 with this and/or related compounds
in order to drive a synthetic chemistry programme aimed at
improving the potency and selectivity of compounds still
further.
Structural features of APE1 make this protein an attractive
target for small molecule inhibitors. A comparison of the
architecture of the catalytic active site in the absence and
presence of bound DNA substrate indicates that there is little
or no remodeling of the active site upon AP site binding
(11,12). This point is reinforced by the molecular docking
study reported here in which the protein structures were
rigid. Using X-ray structures determined in the presence
and absence of DNA, CRT0044876 was seen to favor similar
binding modes in the active site in both cases. Having a ‘pre-
formed’ active site pocket of this sort opens the way to
targeting the catalytic centre of the enzyme prior to the intro-
duction of cellular DNA damage, which should increase the
likelihood of ablating APE1 function in tumors during
chemotherapy.
It is interesting to note that there are many parallels between
our ﬁndings and those presented recently by Wang et al. (31)
and Fung and Demple (32) using an siRNA approach to dis-
able APE1 function. Wang et al. showed that down regulation
ofAPE1was associated with enhancedcytotoxicity and induc-
tion of apoptosis following exposure to alkylating agents,
hydrogen peroxide and other DNA damaging agents (31).
This potentiation of cytotoxicity was very similar to the effects
ofCRT0044876seen inourstudy.Recently,Fungand Demple
(32) observed that siRNA-mediated APE1 depletion led to an
accumulation of AP sites, a reduction in cell proliferation and
an induction of apoptosis in the absence of any other treat-
ments. The results of that study suggest that the primary essen-
tial function of APE1 is likely to be in DNA repair (32).
However, in the present study, CRT0044876 was shown to
be non-toxic to several human cell lines at doses well in excess
of those that potentiated cell killing by alkylating agents.
Taken together, these data would imply that the inherent toxi-
city associated with APE1 depletion by siRNA may be a result
of disabling both the BER functions of APE1 and functions
distinct from DNA repair, such as its recently described and
apparently essential role in acetylation-mediated gene regula-
tion (52). It should be emphasized, however, that this conclu-
sion istentative atthis stageand additional studies are required
to address this point in detail.
In summary, we have identiﬁed small molecule inhibitors of
the APE1 DNA repair enzyme. Amongst these, CRT0044876
(a)
(b)
Figure7. MolecularModeling.CRT0044876isachemicallyknownas7-nitro-
1H-indole-2-carboxylic acid (a). Through molecular modeling studies,
CRT0044876 was found to dock on to the active site of APE1 in two different
low energy conformations (b) designated cluster I (in yellow) and cluster II
(in blue). APE1 is shown as a ribbon structure. Selected active site amino acid
residues are indicated. See text for details.
4722 Nucleic Acids Research, 2005, Vol. 33, No. 15was identiﬁed as a promising lead compound for future devel-
opment. CRT0044876 represents the ﬁrst generation of APE1-
targeting lead compounds for blocking BER during cancer
chemotherapy. Numerous factors, including the pharmacoki-
netics of BER inhibitors in vivo and their potency, will have to
be considered in the design of the next generation of com-
pounds. Nevertheless, CRT0044876 represents a valuable
reagent for probing APE1 function and the BER process in
general in vitro and in vivo.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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